Press review


GSK's shingles vaccine raises hopes for elderly people

Country : Germany, Japan, U.S.

Keywords :
BERLIN, 2 Nov (APM) - GlaxoSmithKline's shingles vaccine Shingrix is boosting hopes for elderly people, Die Welt reports on Friday (p20), without naming the brand name.
The new vaccine is seen as more efficient in people over 60 than the existing vaccine, which can only prevent an outbreak of shingles in 50% of them. Furthermore, the new vaccine can be administered to people treated for an autoimmune disease, which is not possible with the older vaccine, Die Welt reports.
However Shingrix is not reimbursed on a regular basis in Germany yet - only in individual cases or by some health insurance compnaies. Once it has gone through the German commission for vaccinations STIKO in the spring of 2019, the reimbursement may come in effect next year, or in 2020 at the latest, Die Welt says.

Grünenthal buys rights to two AstraZeneca's drugs

Germany's Grünenthal has made the biggest single investment in its history by buying the rights to two AstraZeneca drugs, reported Handelsblatt on Wednesday (p45).
The company will buy the European rights to acid-reflux medicine Nexium (esomeprazole) in Europe and the worldwide rights - excluding the U.S. and Japan - to pain-relief drug Vimovo (naproxen+esomeprazole) (APMHE 60359).

Bayer risks years of legal battle on glyphosate

Bayer will face years of legal battles in the U.S. on carcinogenicity of weed killer glyphosate, Wirtschaftswoche is reporting on Friday (p54-54).
Despite their experience, the two top lawyers hired by Bayer, George Lombardi and Kirby Griffis, were unable to convince the jury in the first trial related to Californian groundkeeper Dewayne Johnson, the weekly says.
Bayer will file an appeal with the California Court of Appeal. Almost 9,000 glyphosate lawsuits are pending in the U.S. and the next legal proceedings will start in February, the weekly added.
U.S. civil law expert David Levine told Wirtschaftswoche that Bayer could try to reach settlement agreements with plaintiffs without acknowledging guilt and thus avoid years of procedures.
The company has already acted that way with its contraceptive pill Yaz and cholesterol-lowering pill Lipobay. According to Levine, a settlement in the glyphosate cases could be in the "one-digit billion dollar range".
Investors have shown their doubts on Bayer's future as the company has lost almost €30 billion on the stock market since it acquired Monsanto in June, Die Welt reported on Sunday (p32).

Bavarian doctors want transparency about pharma sponsors

The Bavarian doctors' association has decided to change its professional code of conduct to preserve doctors' independence vis-à-vis sponsoring pharma companies, Sueddeutsche Zeitung (SZ) said on Monday (p49).
The association has voted at its annual meeting that support for publication and distribution of research results as well as institutional sponsorship and conflicts of interest will be recorded.

Abacus cancels IPO

The Danish parallel trade specialist Abacus Medicine has cancelled the planned stock market float, reported FAZ on Thursday (p20).
Abacus chief executive Flemming Wagner said on Wednesday evening he had decided to wait until the market environment was more favourable.
Abacus had planned to raise about €40 million from its flotation on the Frankfurt Stock Exchange (APMHE 59938).

Sanofi returns to growth thanks to vaccines and orphan drugs

Vaccines and drugs against rare diseases have provided Sanofi with surprisingly good results in the third quarter of 2018, FAZ reported on Thursday (p19) (APMHE 60373).
Sales grew by 3.7% to €9.4 billion euros in the third quarter. At constant exchange rates, net profit improved by 10% to €2.3 billion euros - €160 million more than analysts had expected on average.
Following the announcement, its shares were up 5% on the Paris stock market.

GlaxoSmithKline earnings on the rise

GlaxoSmithKline's earnings have risen in the third quarter thanks to its new herpes zoster vaccine Shingrix, Die Welt (p13) and FAZ (p20) said on Thursday (APMHE 60385).
Adjusted earnings per share (EPS) rose by 10% to 35.5 pence, which was significantly better than analysts' expectations.

EU health commissioner calls for greater investment in prevention in Germany

Germany is investing €3,996 per capita in medical care, 43% more than average in the EU but should invest more in prevention, EU health commissioner Vytenis Andriukaitis said in an interview with Die Welt on Monday (p6).
Andriukaitis added that Germany is ranked 18 in terms of life expectancy (80.7 years) in Europe, while its expenditure on healthcare is the highest in the EU (11.2% of the gross domestic product).



Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to our last stories

Request a trial to assess coverage that includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.